A detailed history of Moody Aldrich Partners LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 300,951 shares of CPRX stock, worth $4.66 Million. This represents 0.89% of its overall portfolio holdings.

Number of Shares
300,951
Previous 307,912 2.26%
Holding current value
$4.66 Million
Previous $5.18 Million 7.32%
% of portfolio
0.89%
Previous 1.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$13.18 - $17.11 $91,745 - $119,102
-6,961 Reduced 2.26%
300,951 $4.8 Million
Q4 2023

Jan 25, 2024

BUY
$11.78 - $17.29 $405,232 - $594,776
34,400 Added 12.58%
307,912 $5.18 Million
Q3 2023

Nov 07, 2023

BUY
$11.69 - $15.02 $129,466 - $166,346
11,075 Added 4.22%
273,512 $3.2 Million
Q2 2023

Jul 28, 2023

BUY
$11.5 - $18.08 $694,082 - $1.09 Million
60,355 Added 29.87%
262,437 $3.53 Million
Q1 2023

Apr 27, 2023

BUY
$14.34 - $21.05 $2.9 Million - $4.25 Million
202,082 New
202,082 $3.35 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $1.59B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Moody Aldrich Partners LLC Portfolio

Follow Moody Aldrich Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Aldrich Partners LLC with notifications on news.